Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow Inc (NQ: HROW )

9.970 -0.300 (-2.92%)
Streaming Delayed Price Updated: 11:38 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harrow Inc

< Previous 1 2 3 4 Next >
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/30
Via Investor Brand Network
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
From Harrow, Inc.
Via Business Wire
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
From Harrow, Inc.
Via Business Wire
Harrow Announces New Appointments to its Board of Directors
From Harrow, Inc.
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/9
Via Investor Brand Network
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Provides Corporate Update
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Partners with Leading Healthcare Market Access Technology Platforms
From Harrow, Inc.
Via Business Wire
Harrow Completes Transfer of the TRIESENCE® New Drug Application
From Harrow, Inc.
Via Business Wire
Harrow to Present at Two Investor Conferences in November
From Harrow, Inc.
Via Business Wire
Harrow Announces Third Quarter 2023 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
From Harrow, Inc.
Via Business Wire
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
From Harrow, Inc.
Via Business Wire
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
From Harrow Health, Inc.
Via Business Wire
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Announces Second Quarter 2023 Financial Results
From Harrow Health, Inc.
Via Business Wire
Harrow Launches VIGAMOX® in the U.S.
From Harrow Health, Inc.
Via Business Wire
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
From Harrow Health, Inc.
Via Business Wire
Harrow Prices $60 Million Public Offering of Common Stock
From Harrow Health, Inc.
Via Business Wire
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
From Harrow Health, Inc.
Via Business Wire
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
From Harrow Health, Inc.
Via Business Wire
Harrow Announces Proposed Public Offering of Common Stock
From Harrow Health, Inc.
Via Business Wire
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
From Harrow Health, Inc.
Via Business Wire
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
From Harrow
Via Business Wire
NASDAQ:HROW Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties at Harrow Health, Inc
San Diego, CA -- (SBWIRE) -- 05/16/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Harrow Health, Inc. 
Via SBWire
Harrow Announces First Quarter 2023 Financial Results
From Harrow Health, Inc.
Via Business Wire
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Harrow
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.